Evolution of human kidney allograft pathology diagnostics through 30 years of the Banff classification process

Table 4 Main changes in the nomenclature and classification of T cell-mediated rejection in the Banff classification over three decades of evolution (1991 to 2019)

Meeting reports, year	Category 4: T cell-mediated rejection1
Banff, 1993	Acute rejection, grades I, II, III
Banff, 1997	Acute/ active cellular rejection
	Types2 I A/B, II A/B, III
Banff, 1997 update (2001)	Acute/ active cellular rejection
	Types I A/B, II A/B, III
Banff, 2005	TCMR2
	Acute, types2 I A/B, II A/B, III
	Chronic active2 (includes only transplant arteriopathy)
Banff, 2007	TCMR
	Acute
	Chronic active (includes only transplant arteriopathy)
Banff, 2013	TCMR
	Acute
	Chronic active (includes only transplant arteriopathy)
Banff, 2015	TCMR
	Acute
	Chronic active TCMR may have tubulointerstitial changes2
Banff, 2017	TCMR
	Acute
	Chronic active TCMR grades I A/B and II defined
Banff, 2019	i-IF/TA and t-IF/TA included in criteria2 (inflammation and tubulitis in areas of scarring)
	In chronic active TCMR with i >1, diagnosis to be combined chronic active and acute TCMR2

¹May coincide with categories 3, 4 and 5 and 6;

²Changes in the nomenclature or criteria. i-IFTA: Inflammation in the scarred cortex; TCMR: T cell mediated rejection; t-IFTA: Tubulitis in mildly to moderately atrophic tubules within the scarred cortex.